PeptiDream

PeptiDream, Sanofi collaborate

Monday, September 14, 2015

PeptiDream, a public Tokyo-based biopharmaceutical company, has announced a multi-target discovery and optimization collaboration with Sanofi. PeptiDream will use its proprietary Peptide Discovery Platform System (PDPS) technology to generate macrocyclic/constrained peptides against multiple targets of interest selected by Sanofi. Sanofi will have the right to develop and commercialize all therapeutic peptides resulting from the collaboration.

[Read More]

PeptiDream, Ipsen expand collaboration

Monday, October 7, 2013

PeptiDream, a Tokyo-based pharmaceutical company, and Ipsen, a global specialty-driven pharmaceutical group, have expanded the scope of their April research collaboration and license option agreement to discover, evaluate, potentially develop and launch therapeutic peptides to treat serious medical conditions in areas of therapeutic focus for Ipsen. The existing collaboration, which combines PeptiDream’s proprietary Peptide Discovery Platform System (PDPS) with Ipsen’s experience in peptide drug discovery and pharmaceutical R&D, will now be extended in scope to enable further therapeutic peptide candidates to enter R&D for additional serious endocrinologic disease.

[Read More]